Erratum: GLP-1-dependent and independent effects and molecular mechanisms of a dipeptidyl peptidase 4 inhibitor in vascular endothelial cells (Molecular Biology Reports DOI:10.1007/s11033-012-2290-8);GLP-1-dependent and independent effects and molecular mechanisms of a dipeptidyl peptidase 4 inhibitor in vascular endothelial cells

Molecular Biology Reports

Volumn 40, Issue 3, 2013, Pages 2273-2279

  Hu, Y ^a   Liu, H B ^a   Simpson, R W ^a,b   Dear, A E ^a  

^a MONASH UNIVERSITY   (Australia)

^b EASTERN HEALTH   (Australia)

Author keywords

Atherosclerosis; DPP IV inhibitor; PAI 1; Vascular adhesion molecules

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; MESSENGER RNA; NUCLEAR RECEPTOR NUR77; PLASMINOGEN ACTIVATOR INHIBITOR 1; SITAGLIPTIN; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ARTICLE; ATHEROGENESIS; CONTROLLED STUDY; ENDOTHELIUM CELL; GENE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; MOLECULAR MECHANICS; NUR77 GENE; PROTEIN EXPRESSION; TRANSCRIPTION REGULATION; VASCULAR ENDOTHELIUM;

EID: 84878391178     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-012-2361-x     Document Type: Erratum

References (32)

1. Hobb FD (2006) Type-2 diabetes mellitus related cardiovascular risk: new options for interventions to reduce risk and treatment goals. Atherosclerosis 7:29-32
2. Vanhoutte PM (2009) Endothelial dysfunction: the first step toward coronary arteriosclerosis. Circ J 73:595-601
3. Morigi M, Angioletti S, Imberti B, Donadelli R, Micheletti G, Figliuzzi M, Remuzzi A, Zoja C, Remuzzi G (1998) Leukocyte-endothelial interaction is augmented by high glucose concentrations and hyperglycemia in a NFkB-dependent fashion. J Clin Invest 101:1905-1915
4. Liu HB, Hu YS, Medcalf RL, Simpson RW, Dear AE (2005) Thiazolidinediones inhibit TNF alpha induction of PAI-1 independent of PPARgamma activation. Biochem Biophys Res Commun 334:30-37
5. Liu HB, Hu YS, Simpson RW, Dear AE (2008) Glucagon-like peptide-1 attenuates tumour necrosis factor-alpha-mediated induction of plasminogen activator inhibitor-1 expression. J Endocrinol 196:57-65
6. Norata GD, Tibolla G, Seccomandi PM, Poletti A, Catapano AL (2006) Dihydrotestosterone decreases tumor necrosis factor-alpha and lipopolysaccharide-induced inflammatory response in human endothelial cells. J Clin Endocrinol Metab 91:546-554
7. Kumar S, Sharma A, Madan B, Singhal V, Ghosh B (2007) Isoliquiritigenin inhibits IkB kinase activity and ROS generation to block TNF-alpha induced expression of cell adhesion molecules on human endothelial cells. Biochem Pharmacol 73:602-1612
8. Iwasaki H, Okamoto R, Kato S, Konishi K, Mizutani H, Yamada N, Isaka N, Nakano T, Ito M (2008) High glucose induces plasminogen activator inhibitor-1 expression through Rho/Rho-kinase-mediated NF-kappaB activation in bovine aortic endothelial cells. Atherosclerosis 196:22-28
9. Kim W, Egan JM (2008) The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev 60:470-512
10. Drab SR (2010) Incretin-based therapies for type 2 diabetes mellitus: current status and future prospects. Pharmacotherapy 30:609-624
11. Matheeussen V, Baerts L, De Meyer G, De Keulenaer G, Van der Veken P, Augustyns K, Dubois V, Scharpe S, De Meester I (2011) Expression and spatial heterogeneity of dipeptidyl peptidases in endothelial cells of conduct vessels and capillaries. Biol Chem 392:189-198
12. Takasawa W, Ohnuma K, Hatano R, Endo Y, Dang NH, Morimoto C (2010) Inhibition of dipeptidyl peptidase 4 regulates microvascular endothelial growth induced by inflammatory cytokines. Biochem Biophys Res Commun 401:7-12
13. Shah Z, Pineda C, Kampfrath T (2011) Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways. Vascul Pharmacol 55:2-9
14. Fadini GP, Avogaro A (2011) Cardiovascular effects of DPP-4 inhibition: beyond GLP-1. Vascul Pharmacol 55:10-16
15. Thornberry NA, Weber AE (2007) Discovery of JANUVIA (Sitagliptin), a selective dipeptidyl peptidase 4 inhibitor for the treatment of type 2 diabetes. Curr Top Med Chem 7:557-568
16. Thornberry NA, Gallwitz B (2009) Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4). Best Pract Res Clin Endocrinol Metab 23:479-486 (Review)
17. Mu J, Petrov A, Eiermann GJ, Woods J, Zhou YP, Li Z, Zycband E, Feng Y, Zhu L, Roy RS, Howard AD, Li C, Thornberry NA, Zhang BB (2009) Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes. Eur J Pharmacol 623:148-154
18. Dobrian AD, Ma Q, Lindsay JW, Leone KA, Ma K, Coben J, Galkina EV, Nadler JL (2011) Dipeptidyl peptidase 4 inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese mice. Am J Physiol Endocrinol Metab 300:E410-E421
19. Shirakawa J, Fujii H, Ohnuma K, Sato K, Ito Y, Kaji M, Sakamoto E, Koganei M, Sasaki H, Nagashima Y, Amo K, Aoki K, Morimoto C, Takeda E, Terauchi Y (2011) Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice. Diabetes 60:1246-1257
20. Cockerill GW, Meyer G, Noack L, Vadas MA, Gamble JR (1994) Characterization of a spontaneously transformed human endothelial cell line. Lab Invest 71:497-509
21. Donnelly D (2012) The structure and function of the glucagon like peptide receptor and its ligands. Br J Pharmacol 166:27-41
22. Hou B, Eren M, Painter CA, Covington JW, Dixon JD, Schoenhard JA, Vaughan DE (2004) Tumor necrosis factor alpha activates the human plasminogen activator inhibitor-1 gene through a distal nuclear factor kappaB site. J Biol Chem 279:18127-18136
23. Collins T, Read MA, Neish AS, Whitley MZ, Thanos D, Maniatis T (1995) Transcriptional regulation of endothelial cell adhesion molecules: NF-kappa B and cytokine-inducible enhancers. FASEB J 9:899-909
24. Gruber F, Hufnagl P, Hofer-Warbinek R, Schmid JA, Breuss JM, Huber-Beckmann R, Lucerna M, Papac N, Harant H, Lindley I, de Martin R, Binder BR (2003) Direct binding of Nur77/NAK-1 to the plasminogen activator inhibitor 1 (PAI-1) promoter regulates TNF alpha -induced PAI-1 expression. Blood 101:3042-3048
25. Hu Y, Liu HB, Simpson RW, Dear AE (2011) PPARγ-independent thiazolidinedione-mediated inhibition of NUR77 expression in vascular endothelial cells. J Endocrinol 208:R1-R7
26. Matsui T, Nishino Y, Takeuchi M, Yamagishi S (2011) Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product-receptor axis. Pharmacol Res 63:383-388
27. Ta NN, Schuyler CA, Li Y (2011) DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in Diabetic apolipoprotein E-deficient mice. J Cardiovasc Pharmacol 58:157-166
28. Hattori S (2011) Sitagliptin reduces albuminuria in patients with type 2 diabetes. Endocr J 58:69-73
29. Ma LJ, Mao SL, Taylor KL, Kanjanabuch T, Guan Y, Zhang Y, Brown NJ, Swift LL, McGuinness OP, Wasserman DH, Vaughan DE, Fogo AB (2004) Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes 53:336-346
30. Eitzman DT, Westrick RJ, Xu Z, Tyson J, Ginsburg D (2000) Plasminogen activator inhibitor-1 deficiency protects against atherosclerosis progression in the mouse carotid artery. Blood 96:4212-4215
31. Yue Z, Bruemmer D (2009) NR4A Orphan nuclear receptors in cardiovascular biology. Drug Discov Today Dis Mech 6:e43-e48
32. Kähne T, Reinhold D, Neubert K, Born I, Faust J, Ansorge S (2000) Signal transduction events induced or affected by inhibition of the catalytic activity of dipeptidyl peptidase 4 (CD26). Adv Exp Med Biol 477:131-137